Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Semax: Neuropeptide for Cognitive Enhancement Research

Back to library
peptide

Semax: Neuropeptide for Cognitive Enhancement Research

13 min read
Cognitive Research
Neuropeptide
Mechanism of Action
Last Updated: May 2026

Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) — developed as an analog of the adrenocorticotropic hormone fragment ACTH(4-7), with an added Pro-Gly-Pro tripeptide extension that significantly extends its biological half-life and CNS activity profile. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, Semax has accumulated a substantial published research record across neuroprotection, brain-derived neurotrophic factor (BDNF) modulation, cognitive function models, and stroke recovery research. For researchers working in neuropeptide pharmacology, CNS signalling, or neuroplasticity, Semax represents one of the most extensively studied synthetic peptide analogs in the cognitive neuroscience literature. Pure Grade Labs supplies research-grade Semax 10mg verified to ≥99% purity by HPLC, with a batch-specific COA included with every order. For researchers studying both the anxiolytic and cognitive dimensions of neuropeptide pharmacology, Selank — a tuftsin analog developed by the same research group — is frequently studied alongside Semax.

Key Takeaways

  • Semax is a 7-amino acid synthetic peptide (MEHFPGP) — a structural analog of ACTH(4-7) with a stabilising Pro-Gly-Pro C-terminal extension. CAS: 80714-61-0. Molecular weight: 813.94 Da.
  • Primary research interest: BDNF and NGF modulation. Published studies in rodent models demonstrate that Semax upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cerebral cortex — neurotrophic factors central to synaptic plasticity and neuronal survival.
  • Neuroprotection in ischaemia models: Semax has been studied extensively in experimental stroke and cerebral ischaemia models, demonstrating reductions in lesion volume and improvements in neurological outcome scores in preclinical research.
  • Melanocortin receptor activity: Semax binds to melanocortin receptors (MC1R, MC4R, MC5R), which are implicated in neuromodulation, inflammation, and synaptic signalling — providing a mechanistic basis for its observed CNS effects in research models.
  • Russian clinical research context: Semax has been approved as a drug in Russia (under the trade name Semax nasal drops) and has been the subject of clinical trials in stroke recovery and cognitive function — providing a clinical literature base unusually substantial for a synthetic peptide. For research purposes only outside Russia.
813.94 Da
Molecular weight of Semax (CAS: 80714-61-0) — heptapeptide MEHFPGP, synthetic ACTH(4-7) analog with Pro-Gly-Pro extension
BDNF
Primary neurotrophic factor upregulated by Semax in hippocampal and cortical tissue — central to synaptic plasticity and neuronal survival research
MC4R
Key melanocortin receptor targeted by Semax — implicated in neuromodulation, CNS inflammation signalling, and synaptic plasticity pathways
1993
Year Semax was registered as a drug in Russia — providing over 30 years of clinical and research literature for neuropeptide researchers

Research-Grade Semax — UK Supply

Semax 10mg. HPLC-verified ≥99% purity. Batch-specific COA included. For laboratory research purposes only.

View Semax 10mg →

What Is Semax? Structure and Origin

Semax (MEHFPGP) is a seven-amino-acid synthetic peptide created by extending the ACTH(4-7) tetrapeptide (Met-Glu-His-Phe) with a Pro-Gly-Pro tripeptide at the C-terminus. The parent fragment ACTH(4-7) was identified in the 1970s–80s as the behaviorally active core of the adrenocorticotropic hormone molecule — the portion responsible for cognitive and neurotrophic effects without the steroidogenic activity of full-length ACTH.

The Pro-Gly-Pro extension was added by researchers at the Institute of Molecular Genetics (IMGen), Russian Academy of Sciences, to increase the metabolic stability of the ACTH(4-7) sequence. Native ACTH(4-7) is rapidly degraded by serum enzymes (particularly prolyl endopeptidase and related peptidases); the C-terminal extension substantially reduces this degradation, extending the effective research half-life of the compound in experimental systems. This stabilisation is why Semax has been more amenable to systemic and intranasal research models than the parent ACTH fragment.

The compound was developed by Nikolai Myasoedov and colleagues at IMGen over the 1980s and was registered as a pharmaceutical drug in Russia in 1993. It is commercially available in Russia as a 0.1% nasal spray solution under the brand name Semax. Outside Russia, it has no pharmaceutical approval and is available only as a research chemical. CAS number: 80714-61-0. Molecular formula: C37H51N9O10S. Molecular weight: 813.94 Da.

Mechanism of Action: How Semax Works at the Molecular Level

Melanocortin Receptor Binding

Semax exerts its primary direct receptor effects through the melanocortin receptor family. The ACTH(4-7) core sequence (Met-Glu-His-Phe) retains affinity for melanocortin receptors MC1R, MC4R, and MC5R. The MC4R receptor is particularly relevant to CNS function: it is expressed throughout the brain, including the hypothalamus, hippocampus, and cerebral cortex, and its activation is associated with neuromodulation, synaptic signalling, and regulation of inflammatory cascades in the CNS.

MC4R activation has been linked in published research to neurotrophic factor upregulation, anti-inflammatory signalling (via modulation of NF-κB pathways), and enhancement of long-term potentiation (LTP) — the synaptic mechanism underlying learning and memory consolidation. These effects provide a mechanistic basis for the cognitive and neuroprotective properties observed in Semax research models.

BDNF and NGF Upregulation

Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are the most studied downstream effects of Semax in the published neuroscience literature. Dolotov et al. (2006) demonstrated that Semax administration to rats produced significant upregulation of BDNF mRNA and protein in the hippocampus and frontal cortex. Agapova et al. (2007) extended this work to BDNF-heterozygote mouse models, confirming that Semax modulated BDNF expression even in genetically compromised systems, with implications for neurodegeneration research models.

BDNF is a critical mediator of synaptic plasticity, neuronal survival, and adult neurogenesis — particularly in the hippocampus. Its upregulation by Semax in preclinical models has driven significant research interest in stroke recovery, cognitive decline models, and conditions associated with reduced neurotrophic factor expression. NGF upregulation complements this by supporting cholinergic neuronal populations in basal forebrain regions implicated in memory and learning.

Dopaminergic and Serotonergic Modulation

Published studies in rodent models have observed that Semax modulates dopaminergic and serotonergic neurotransmitter systems in forebrain regions. Increased dopamine and serotonin turnover has been reported in the striatum and frontal cortex following Semax administration — findings consistent with the compound’s observed effects in attention and cognitive flexibility models. These monoaminergic effects are understood to be secondary to melanocortin receptor activation rather than direct receptor binding at dopamine or serotonin receptors.

In a 2006 study by Dolotov et al., researchers administered Semax to adult Wistar rats and measured BDNF mRNA expression across five brain regions. In the frontal cortex, hippocampus, and striatum, BDNF expression was significantly elevated at 1 hour and 24 hours post-administration relative to vehicle controls. The finding was notable because BDNF upregulation this pronounced — in the hippocampus in particular — placed Semax among a small group of compounds capable of acutely modulating neurotrophic factor expression without the gene-delivery methods typically required to achieve similar effects in research models.

Semax in Neuroprotection Research

The neuroprotection research profile of Semax is the most developed area of its published literature. The primary experimental model has been middle cerebral artery occlusion (MCAO) in rodents — the standard preclinical model for focal cerebral ischaemia and stroke — alongside transient global ischaemia models.

Focal Cerebral Ischaemia Models

Romanova et al. and subsequent studies at the Cardiology Research Centre in Moscow demonstrated that Semax administration in MCAO models reduced infarct volume and improved neurological deficit scores relative to controls. The proposed mechanism involves reduced glutamate excitotoxicity (through NMDA receptor modulation downstream of MC4R signalling) alongside BDNF-mediated support of peri-infarct neuronal populations.

The anti-inflammatory dimension of neuroprotection has also been explored: Semax administration was associated with reduced expression of pro-inflammatory cytokines (TNF-α, IL-1β) in ischaemic brain tissue in rodent models, consistent with MC4R’s known role in modulating the NF-κB inflammatory cascade. These findings positioned Semax as a multi-mechanism neuroprotective agent in preclinical settings — acting on both excitotoxic and inflammatory arms of ischaemic injury.

Russian Clinical Research: Stroke Recovery

Semax’s approval as a pharmaceutical drug in Russia for ischaemic stroke treatment provides a clinical research base that is unusual for synthetic peptide compounds. Russian clinical trials (Gusev EI et al.; Myasoedov NF et al.) reported improvements in neurological recovery scores in patients administered Semax via intranasal route in the acute and subacute post-stroke period. These trials, while conducted to standards that differ from FDA or EMA requirements, represent the most directly clinical data in the Semax literature and have driven ongoing research interest in peptide-based neuroprotection strategies.

Cognitive Function Research

Outside the neuroprotection context, Semax has been studied in standard cognitive function models — spatial learning, memory consolidation, attention, and cognitive flexibility paradigms in rodents. The Morris water maze and radial arm maze are the most commonly used behavioural models in the published Semax literature.

Memory and Learning Models

Semenova TP et al. and Shevchenko KV et al. demonstrated improved performance in spatial memory tasks in rats treated with Semax relative to vehicle controls. Latency to platform in Morris water maze trials was reduced, and probe trial performance (measuring spatial memory retention) was improved in treated groups. The hippocampal BDNF upregulation observed in neurochemical studies correlates mechanistically with these behavioural findings, since hippocampal BDNF signalling through the TrkB receptor is a known requirement for long-term potentiation and spatial memory consolidation.

Attention and Executive Function

Russian clinical and semi-clinical research has also explored Semax in attention deficit models and in healthy subjects performing cognitively demanding tasks. The attention-modulating effects are attributed to dopaminergic and noradrenergic activity in prefrontal cortex circuits — consistent with MC4R’s distribution in the frontal cortex and known involvement in prefrontal executive function. These investigations remain in the preclinical and early clinical domain; they have not been replicated in large-scale Western clinical trials.

Source Semax for Your Research

Semax 10mg — HPLC ≥99% purity. Batch COA. UK supply. Also available: Selank 10mg and the Cognitive Focus Research Stack.

View Semax 10mg →

Safety Profile in the Published Literature

The Semax safety literature derives primarily from Russian preclinical and clinical research. In rodent models, Semax has demonstrated a favourable acute and subacute toxicology profile at doses used in experimental protocols. Lethal dose (LD50) data from rodent studies places Semax in a low-toxicity classification, with no observable adverse effects at the doses studied in the published cognitive and neuroprotection literature.

In the Russian clinical trial context, adverse event reporting has been limited. Intranasal administration (the route studied in the clinical literature) has been associated with occasional mild local irritation — nasal mucosal effects — but systemic adverse events were not reported at clinically relevant doses in published trials. No significant hormonal disruption has been observed in the Semax literature, which is consistent with the compound’s design: the ACTH(4-7) fragment retains cognitive effects without the corticotropic (steroidogenic) activity of full-length ACTH.

It is important to note that the safety literature for Semax is primarily Russian in origin and does not meet the regulatory evidence standards required for pharmaceutical approval in the UK, EU, or USA. Semax has no marketing authorisation or clinical trial approval outside Russia. All research using Semax outside Russia is conducted under the research chemical framework.

Semax vs. Related Neuropeptides

Compound Structure Primary Mechanism Primary Research Area
Semax MEHFPGP (7 AA) MC4R agonism, BDNF/NGF upregulation Neuroprotection, cognitive function, stroke recovery
Selank TKPRPGP (7 AA) GABA-A modulation, enkephalinase inhibition Anxiolytic activity, GAD models, immunomodulation
ACTH(4-7) (parent) MEHF (4 AA) MC receptor binding — rapid degradation Reference compound — short half-life limits research utility
BPC-157 15 AA — gastric VEGFR2, growth factor pathways Peripheral tissue repair, cytoprotection — minimal CNS profile

Research Applications and Experimental Contexts

Semax is used in research across several experimental domains. In neuropharmacology, it serves as a tool compound for investigating melanocortin receptor function in cognitive and neuroprotective contexts. In neurotrophic factor research, it provides a pharmacological means of upregulating endogenous BDNF/NGF expression without viral gene delivery — enabling researchers to study the downstream consequences of neurotrophic factor elevation in intact neural tissue.

In stroke and ischaemia research, Semax has been employed as an active comparator and as a potential intervention compound in rodent MCAO models. Its availability as a clinically approved drug in Russia (with associated clinical data) makes it a compound of interest for researchers seeking peptide-based neuroprotective strategies with at least some clinical translation precedent.

Researchers studying cognitive enhancement mechanisms — neuroplasticity, LTP, memory consolidation — use Semax as a BDNF-upregulating tool compound alongside direct BDNF administration, TrkB agonists, and exercise-induced neurotrophin studies. Its distinct mechanism (indirect BDNF elevation via MC4R) differentiates it from direct receptor approaches and allows mechanistic dissection of the pathway.

Frequently Asked Questions

What is Semax used for in research?

In research contexts, Semax is used primarily as a tool compound for investigating BDNF/NGF modulation via melanocortin receptor pathways, neuroprotection in ischaemia models, and cognitive function in behavioural paradigms including spatial memory and attention tasks. Its Russian clinical approval for stroke treatment provides researchers with an unusual degree of clinical context for a synthetic peptide research compound.

How does Semax differ from Selank?

While both Semax and Selank are 7-amino acid synthetic neuropeptides developed at the same Russian research institute, their mechanisms and primary research profiles differ substantially. Semax acts primarily via melanocortin receptors and BDNF/NGF upregulation, with the majority of its literature focused on neuroprotection and cognitive function. Selank acts primarily via GABA-A receptor modulation and enkephalinase inhibition, with the majority of its literature focused on anxiolytic activity and generalised anxiety models. They are frequently studied together in research programmes that span both cognitive and anxiolytic dimensions of neuropeptide pharmacology.

Is Semax approved in the UK?

Semax has no pharmaceutical marketing authorisation in the UK, EU, or USA. It is approved as a drug only in Russia, where it is available as a prescription nasal spray. Outside Russia, Semax is available strictly as a research chemical for laboratory research purposes only. It is not for human consumption in the UK.

What purity standard does Pure Grade Labs maintain for Semax?

Pure Grade Labs supplies Semax 10mg verified to ≥99% purity by HPLC analysis. A batch-specific Certificate of Analysis (COA) including purity data, batch number, test date, analytical method, and laboratory details is included with every order. This batch-specific documentation allows researchers to verify the analytical basis for the purity figure stated.

How should Semax be stored in a laboratory setting?

Lyophilised (freeze-dried) Semax powder should be stored at −20°C, protected from light and moisture. Under these conditions, stability is maintained for the duration of the stated shelf life. Once reconstituted with bacteriostatic water for laboratory use, the solution should be stored at 4°C and used within approximately four weeks. Avoid repeated freeze-thaw cycles on reconstituted peptide solutions.

Semax & Selank — Cognitive Research Compounds

Both available individually or as the Cognitive Focus Research Stack. HPLC-verified. Batch COA. UK supply.

View Semax 10mg →

Summary

Semax (MEHFPGP) is a synthetic ACTH(4-7) analog with an established published research record across neuroprotection, BDNF/NGF modulation, and cognitive function models. Its mechanism — melanocortin receptor binding driving downstream neurotrophic factor upregulation — is well-characterised in the preclinical literature, and its Russian clinical approval for stroke treatment provides a translational context unusual for synthetic peptide research compounds.

For researchers working in neuropeptide pharmacology, neuroplasticity, or neuroprotection, Semax offers a tool compound with both mechanistic specificity and a clinically contextualised research history. The combination of MC4R agonism, BDNF/NGF upregulation, dopaminergic modulation, and anti-inflammatory signalling gives it a multi-mechanism profile that differentiates it from single-target cognitive research tools.

Pure Grade Labs supplies research-grade Semax 10mg verified to ≥99% purity by HPLC with a batch-specific COA. Researchers working across cognitive and anxiolytic dimensions may also wish to consider Selank 10mg, or the Cognitive Focus Research Stack combining both compounds.

References

  1. Dolotov OV et al. (2006). Semax, an analog of ACTH(4-7) with cognitive effects, regulates BDNF and TrkB expression in the rat hippocampus. Behavioural Brain Research. 168(1):96-103.
  2. Agapova TY et al. (2007). Effects of ACTH(4-7)PGP (Semax) on mRNA expression of BDNF and its receptor TrkB in various brain structures of BDNF-heterozygous mice. Doklady Biological Sciences. 412:18-20.
  3. Nezavibathko VN et al. (1997). Semax, a new amino acid peptide drug for the management of cerebrovascular disorders. Drug Development Research. 41(4):249-252.
  4. Semenova TP et al. (2002). Comparison of the effects of Semax and its C-terminal peptide PGP on the behaviour and neurochemical parameters of rat brain. Eksperimental’naia i klinicheskaia farmakologiia. 65(3):53-55.
  5. Myasoedov NF et al. (1999). Analysis of adaptive brain effects of Semax. Zhurnal vysshei nervnoi deyatelnosti. 49(3):534-39.
  6. Gusev EI, Skvortsova VI. (2003). Brain Ischemia. Kluwer Academic/Plenum Publishers. ISBN 0306474824. (Clinical stroke recovery data context.)
Disclaimer: This article is for research and informational purposes only. Semax is not approved as a pharmaceutical drug in the UK, EU, or USA. Research-grade Semax from Pure Grade Labs is sold for in vitro laboratory research purposes only and is not intended for human consumption or therapeutic use. This content does not constitute medical advice. Purchasers are responsible for compliance with all applicable regulations in their jurisdiction.